Related references
Note: Only part of the references are listed.PI3Kδ as a Novel Therapeutic Target in Pathological Angiogenesis
Wenyi Wu et al.
DIABETES (2020)
Targeting PI3K and AMPKα Signaling Alone or in Combination to Enhance Radiosensitivity of Triple Negative Breast Cancer
Jeremy Johnson et al.
CELLS (2020)
p110 δ PI3K as a therapeutic target of solid tumours
Lydia Xenou et al.
CLINICAL SCIENCE (2020)
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Jing Yang et al.
MOLECULAR CANCER (2019)
Downregulation of exosomal CLEC3B in hepatocellular carcinoma promotes metastasis and angiogenesis via AMPK and VEGF signals
Wenjuan Dai et al.
CELL COMMUNICATION AND SIGNALING (2019)
Efficacy of PI3K inhibitors in advanced breast cancer
B. Verret et al.
ANNALS OF ONCOLOGY (2019)
PIK3CD induces cell growth and invasion by activating AKT/GSK-3β/β-catenin signaling in colorectal cancer
Jing-Song Chen et al.
CANCER SCIENCE (2019)
The regulatory effect of microRNA-21a-3p on the promotion of telocyte angiogenesis mediated by PI3K (p110α)/AKT/mTOR in LPS induced mice ARDS
Yile Zhou et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2019)
PIK3CB/p110 beta is a selective survival factor for glioblastoma
Kevin J. Pridham et al.
NEURO-ONCOLOGY (2018)
Long non-coding RNA UBE2CP3 enhances HCC cell secretion of VEGFA and promotes angiogenesis by activating ERK1/2/HIF-1 alpha/VEGFA signalling in hepatocellular carcinoma
Jinduan Lin et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
Pharmacological inactivation of the PI3K p110δ prevents breast tumour progression by targeting cancer cells and
Evangelia Goulielmaki et al.
CELL DEATH & DISEASE (2018)
Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases
Gillian L. Dornan et al.
FRONTIERS IN IMMUNOLOGY (2018)
Class I Phosphoinositide 3-Kinase PIK3CA/p110α and PIK3CB/p110β Isoforms in Endometrial Cancer
Fatemeh Mazloumi Gavgani et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Endometrial cancer cells exhibit high expression of p110β and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation
Thomas Karlsson et al.
ONCOTARGET (2017)
Molecular mechanism of activation of class IA phosphoinositide 3-kinases (PI3Ks) by membrane-localized HRas
Braden D. Siempelkamp et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models
Svenja Noelting et al.
PLOS ONE (2017)
Inhibition of p110δ PI3K prevents inflammatory response and restenosis after artery injury
Antonio Bilancio et al.
BIOSCIENCE REPORTS (2017)
Increased Expression of Phosphatidylinositol 3-Kinase p110α and Gene Amplification of PIK3CA in Nasopharyngeal Carcinoma
Wai Kien Yip et al.
PATHOLOGY & ONCOLOGY RESEARCH (2016)
Effect of EGFR and p-AKT Overexpression on Chromosomal Instability in Gastric Cancer
Yuichi Hisamatsu et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
p110 and p110 isoforms of PI3K signaling: are they two sides of the same coin?
Paramjeet Singh et al.
FEBS LETTERS (2016)
PI3K inhibitors as new cancer therapeutics: implications for clinical trial design
Cristian Massacesi et al.
ONCOTARGETS AND THERAPY (2016)
Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy
Klaus Okkenhaug et al.
CANCER DISCOVERY (2016)
Class IA Phosphatidylinositol 3-Kinase Isoform p110α Mediates Vascular Remodeling
Marius Vantler et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)
Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma
Qingshan Yang et al.
CLINICAL CANCER RESEARCH (2015)
ARID2, p110α, p53, and β-catenin protein expression in hepatocellular carcinoma and dinicopathologic implications (vol 46, pg 583, 2015)
Jason You et al.
HUMAN PATHOLOGY (2015)
Expression and significance of CD44 and p-AKT in pancreatic head cancer
Li Xiaoping et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2015)
The evolving epidemiology of hepatocellular carcinoma: a global perspective
Michael C. Wallace et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2015)
A Macrophage-Dominant PI3K Isoform Controls Hypoxia-Induced HIF1α and HIF2α Stability and Tumor Growth, Angiogenesis, and Metastasis
Shweta Joshi et al.
MOLECULAR CANCER RESEARCH (2014)
Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
Khaled Ali et al.
NATURE (2014)
Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
Akintunde Akinleye et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
p110 delta P13 kinase pathway: emerging roles in cancer
Niki Tzenaki et al.
FRONTIERS IN ONCOLOGY (2013)
High levels of p110δ PI3K expression in solid tumor cells suppress PTEN activity, generating cellular sensitivity to p110δ inhibitors through PTEN activation
Niki Tzenaki et al.
FASEB JOURNAL (2012)
Promotion of hepatocellular carcinoma metastasis through matrix metalloproteinase activation by epithelial-mesenchymal transition regulator Twist1
Xiu-lan Zhao et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2011)
PI3K/AKT/mTOR pathway in angiogenesis
Jayashree Karar et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2011)
Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration
Mariona Graupera et al.
NATURE (2008)
Essential roles of PI(3)K-p110β in cell growth, metabolism and tumorigenesis
Shidong Jia et al.
NATURE (2008)
Oncogenic signaling of class IPI3K isoforms
A. Denley et al.
ONCOGENE (2008)
Share Paper
